Friday, July 10, 2026 | 11:26 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Page 13 - Zydus Lifesciences

DCGI okays emergency use of Zydus' two-jab Covid-19 vaccine for 12 yrs-plus

With this, vaccine will now be administered on day 0 and day 28. Earlier, it was approved as a triple dose on day 0, day 28 and day 56

DCGI okays emergency use of Zydus' two-jab Covid-19 vaccine for 12 yrs-plus
Updated On : 26 Apr 2022 | 4:27 PM IST

Covid-19: Zydus gets SEC approval for two-dose regimen of ZyCov-D

Zydus to conduct mixing trials to test vax efficacy after two shots of Covishield/Covaxin

Covid-19: Zydus gets SEC approval for two-dose regimen of ZyCov-D
Updated On : 15 Apr 2022 | 2:25 AM IST

Zydus Lifesciences gets 3 observations from USFDA for Vadodara plant

Zydus Lifesciences on Thursday said the US health regulator has issued three observations after inspecting its Jarod (Vadodara) based manufacturing facility. The US Food and Drug Administration (USFDA) inspected the injectable facility from February 24 to March 10, 2022. The inspection closed with three observations, the drug firm said in a regulatory filing. "We are confident of addressing and resolving the issues to the satisfaction of USFDA. We remain committed to building a quality culture across our entire manufacturing network, and are committed to remain compliant with high standards of good manufacturing practices across our network," Zydus Lifesciences stated. As per the US health regulator, an FDA Form 483 (observation) is issued to a firm's management at the conclusion of an inspection when investigators have observed any conditions that in their judgment may constitute violations of Food Drug and Cosmetic (FD&C) Act and related Act.

Zydus Lifesciences gets 3 observations from USFDA for Vadodara plant
Updated On : 10 Mar 2022 | 3:34 PM IST